Cognitive-behavioral Therapy for Generalized Anxiety Disorder in Primary Care

Not Applicable

Completed

• Conditions: Generalized Anxiety Disorder
• Interventions: Behavioral: Metacognitive therapy; Behavioral: Intolerance of uncertainty therapy

• Registration Number: NCT03621371
• Lead Sponsor: Karolinska Institutet

Brief Summary

The feasibilty and preliminary comparative effectiveness of two methods of cognitive-behavioral therapy - metacognitive therapy and intolerance of uncertainty therapy - for primary care patients with generalized anxiety disorder is investigated in a pilot study using a randomized controlled design. Purpose of the study is to examine the feasibility of a full-scale randomized controlled trial. Research questions primarily concern recruitment, measurement, and adherence.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-06-15
• Study First Submitted: 2018-06-28
• Study First Submitted QC: 2018-08-07
• Study First Posted: 2018-08-08
• Primary Completion: 2019-11-30
• Study Completion: 2019-11-30
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-01
• Last Update Posted: 2020-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• Primary diagnosis of generalized anxiety disorder
• Age 18 years or above
• Being able to understand and speak Swedish without interpreter support

Read More

Exclusion Criteria

• Psychosis, bipolar disorder, severe depressive symptoms, risk of suicid, substance use disorder, intellectual disability
• Simultaneous psychological treatment
• If pharmacological treatment, it needs to be stable prior to and during treatment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Metacognitive therapy	Metacognitive therapy	-
Intolerance of uncertainty therapy	Intolerance of uncertainty therapy	-

Primary Outcome Measures

Name	Time	Method
Penn State Worry Questionnaire - measure of symptom change	Change from baseline symptoms at 12 weeks	A self-reported symptom measure of worry

Trial Locations

Locations (1)

Liljeholmen Primary Health Care Center; 🇸🇪 Stockholm, Sweden